A call to arms: the imperative for antimicrobial stewardship.

Antimicrobial resistance is a major public health crisis. The prevalence of drug-resistant organisms, such as the emerging NAP1 strain of Clostridium difficile, now highly resistant to fluoroquinolones, Acinetobacter species, Klebsiella pneumoniae carbapenemase-producing organisms, and methicillin-resistant Staphylococcus aureus, is increasing nationwide. The sources of antimicrobial resistance are manifold, but there is a well-documented causal relationship between antimicrobial use and misuse and the emergence of antimicrobial-resistant pathogens. As the development of new antimicrobial agents is on the decline, the medical community, across all specialties and in conjunction with public health services, must develop and implement programs and strategies designed to preserve the integrity and effectiveness of the existing antimicrobial armamentarium. Such strategies are collectively known as antimicrobial stewardship programs and have the potential to minimize the emergence of resistant pathogens.

[1]  B. Limbago,et al.  Complete Restriction of Fluoroquinolone Use to Control an Outbreak of Clostridium difficile Infection at a Community Hospital , 2009, Infection Control & Hospital Epidemiology.

[2]  D. Gerding.  Global Epidemiology of Clostridium difficile Infection in 2010 , 2010, Infection Control & Hospital Epidemiology.

[3]  J. Bartlett,et al.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .

[5]  D. Hooper,et al.  Authors' Reply to article "Hospital-acquired infections due to gram-negative bacteria" , 2010 .

[6]  Andres F Zuluaga,et al.  Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator , 2010, Antimicrobial Agents and Chemotherapy.

[7]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Pruett.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .

[9]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[10]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[11]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.

[12]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults : 2010 Update by the Society for Healthcare Epidemiology of America ( SHEA ) and the Infectious Diseases Society of America , 2010 .

[13]  P. Mehler,et al.  Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Falagas,et al.  Nephrotoxicity of colistin: new insight into an old antibiotic. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Anton Y Peleg,et al.  Hospital-acquired infections due to gram-negative bacteria. , 2010, The New England journal of medicine.

[16]  Lee H. Harrison,et al.  Health care-associated invasive MRSA infections, 2005-2008. , 2010, JAMA.

[17]  E. Kuijper,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  J. Bartlett,et al.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Bissell.  An Antimicrobial Stewardship Program's Impact with Rapid Polymerase Chain Reaction Methicillin-Resistant Staphylococcus aureus/S. aureus Blood Culture Test in Patients with S. aureus Bacteremia , 2012 .

[20]  A. So,et al.  Globalisation and antibiotic resistance , 2010, BMJ : British Medical Journal.

[21]  S. Tschudin-Sutter,et al.  Hand hygiene in the intensive care unit. , 2010, Critical care medicine.

[22]  J. Bartlett.  Antibiotic-associated pseudomembranous colitis. , 1979, Hospital practice.

[23]  J. Bartlett,et al.  Erratum: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America (Clinical Infectious Diseases (March 1, 2006) 42 (657-668)) , 2006 .

[24]  C. Weenink,et al.  Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.

[25]  A. MarioCalvo,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. A randomized trial. Chastre J, Wolff M, Fagon JY, Chevret S et al. JAMA 2003; 290: 2588-98 , 2004 .

[26]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[27]  L. Valiquette,et al.  Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec , 2005, Canadian Medical Association Journal.

[28]  Jian Li,et al.  Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production , 2010, Antimicrobial Agents and Chemotherapy.

[29]  Jon Brazier,et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.

[30]  Guang-xi Li,et al.  Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .

[31]  Heikki Peltola,et al.  Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.